D Nathan

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
    David G Nathan
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Genome Med 1:114. 2009
  2. ncbi Musings on genome medicine: abuse of genetic tests
    David G Nathan
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Genome Med 1:18. 2009
  3. ncbi Musings on genome medicine: the Obama effect
    David G Nathan
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Genome Med 1:30. 2009
  4. ncbi Musings on genome medicine: cancer genetics and the promise of effective treatment
    David G Nathan
    Dana Farber Cancer Institute, Binney Street, Boston, MA 02115, USA
    Genome Med 1:49. 2009
  5. ncbi Musings on genome medicine: gene therapy
    David G Nathan
    Dana Farber Cancer Institute, Binney Street, Boston, MA 02115, USA
    Genome Med 1:38. 2009
  6. ncbi The several Cs of translational clinical research
    David G Nathan
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 115:795-7. 2005
  7. ncbi A life-long quest to understand and treat genetic blood disorders
    David G Nathan
    Harvard Medical School, Dana Farber Cancer Institute, Children s Hospital, Boston, MA 02115, USA
    Cell 143:17-20. 2010
  8. ncbi Thalassemia: the continued challenge
    David G Nathan
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Ann N Y Acad Sci 1054:1-10. 2005
  9. ncbi NIH support for basic and clinical research: biomedical researcher angst in 2006
    David G Nathan
    Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass 02115, USA
    JAMA 295:2656-8. 2006
  10. ncbi Acceptance of the 2003 John Howland Award: a journey in clinical research
    David G Nathan
    Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, U.S.A
    Pediatr Res 56:169-76. 2004

Detail Information

Publications35

  1. ncbi Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
    David G Nathan
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Genome Med 1:114. 2009
    ..Preventive strategies involving carrier detection should be a priority toward the successful management of these conditions...
  2. ncbi Musings on genome medicine: abuse of genetic tests
    David G Nathan
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Genome Med 1:18. 2009
    ..The wide general publication of a putative genetic test for athletic supremacy is clearly an abuse of genetics and reveals an undercurrent of hucksterism in biomedical science...
  3. ncbi Musings on genome medicine: the Obama effect
    David G Nathan
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Genome Med 1:30. 2009
    ..The inauguration of the Obama administration is likely to enhance the role of genome medicine in clinical care and national economics...
  4. ncbi Musings on genome medicine: cancer genetics and the promise of effective treatment
    David G Nathan
    Dana Farber Cancer Institute, Binney Street, Boston, MA 02115, USA
    Genome Med 1:49. 2009
    ..Although there are serious technological and cost hurdles to surmount and resistance and continued mutation will be a constant problem, the way is clear to rational therapy...
  5. ncbi Musings on genome medicine: gene therapy
    David G Nathan
    Dana Farber Cancer Institute, Binney Street, Boston, MA 02115, USA
    Genome Med 1:38. 2009
    ..The field may be poised to move forward more rapidly, but many barriers have yet to be surmounted...
  6. ncbi The several Cs of translational clinical research
    David G Nathan
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 115:795-7. 2005
    ..The following is what I try to say to them...
  7. ncbi A life-long quest to understand and treat genetic blood disorders
    David G Nathan
    Harvard Medical School, Dana Farber Cancer Institute, Children s Hospital, Boston, MA 02115, USA
    Cell 143:17-20. 2010
    ....
  8. ncbi Thalassemia: the continued challenge
    David G Nathan
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Ann N Y Acad Sci 1054:1-10. 2005
    ..The review goes on to emphasize pharmaceutical efforts to induce fetal hemoglobin synthesis in thalassemic red cells and ends with a discussion of oral iron chelators, stem cell transplant, and the status of gene therapy...
  9. ncbi NIH support for basic and clinical research: biomedical researcher angst in 2006
    David G Nathan
    Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass 02115, USA
    JAMA 295:2656-8. 2006
  10. ncbi Acceptance of the 2003 John Howland Award: a journey in clinical research
    David G Nathan
    Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, U.S.A
    Pediatr Res 56:169-76. 2004
  11. ncbi Musings on genome medicine: cholesterol and coronary artery disease
    David G Nathan
    Dana Farber Cancer Institute, Binney Street, Boston, MA 02115, USA
    Genome Med 1:60. 2009
    ..Diabetes greatly increases the risk at any cholesterol level. Coronary artery disease and cancer are linked by a common protein - an apoptotic protein that also functions as a regulator of insulin secretion...
  12. ncbi Comprehensive cancer centres and the war on cancer
    D Nathan
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 1:240-5. 2001
    ....
  13. ncbi Careers in translational clinical research-historical perspectives, future challenges
    David G Nathan
    Dana-Farber Cancer Institute, 44 Binney St, Room D1642, Boston, MA 02115, USA
    JAMA 287:2424-7. 2002
  14. ncbi Acceptance of the 2006 Kober medal
    David G Nathan
    Faber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 117:1107-13. 2007
  15. ncbi Musings on genome medicine: Hepatitis C
    David G Nathan
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Genome Med 2:4. 2010
    ..The only current approach for end-stage disease is liver transplant, which ironically does not cure the condition, and thus poses a clinical dilemma in the face of liver-donor shortage...
  16. ncbi Musings on genome medicine: the slow but inexorable process of medical care reform in the United States
    David G Nathan
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Genome Med 1:94. 2009
    ....
  17. ncbi Musings on genome medicine: the Obama effect redux
    David G Nathan
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Genome Med 1:86. 2009
    ....
  18. ncbi Clinical research: a tale of two studies
    David G Nathan
    Trans Am Clin Climatol Assoc 114:219-30; discussion 230-2. 2003
    ..In this paper I present two examples of academic/pharmaceutical company collaborations, both in search of a similar drug. The cases illustrate both some important hazards and accomplishments of clinical research...
  19. ncbi The cancer treatment revolution
    David G Nathan
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Trans Am Clin Climatol Assoc 118:317-23. 2007
  20. ncbi Pulmonary hypertension and nitric oxide depletion in sickle cell disease
    H Franklin Bunn
    Division of Hematology, Department of Medicine, Harvard Medical School, Boston, MA, USA
    Blood 116:687-92. 2010
    ....
  21. ncbi Targeting the cell death-survival equation
    Edward J Benz
    Dana-Farber Cancer Institute, Harvard University, Boston, MA 02115, USA
    Clin Cancer Res 13:7250-3. 2007
  22. ncbi 2006 Association of American Physicians George M. Kober Medal. Introduction of David G. Nathan, MD
    Edward J Benz
    Faber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 117:1107-11. 2007
  23. ncbi Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia
    Hanna T Gazda
    Division of Genetics, Children s Hospital Boston, Boston, MA 02115, USA
    Am J Hum Genet 79:1110-8. 2006
    ..This finding strongly suggests that DBA is a disorder of ribosome synthesis and that mutations in other RP or associated genes that lead to disrupted ribosomal biogenesis and/or function may also cause DBA...
  24. ncbi A novel diagnostic screen for defects in the Fanconi anemia pathway
    Akiko Shimamura
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 100:4649-54. 2002
    ..A combination of retroviral gene transfer and FANCD2 immunoblotting provides a rapid subtyping assay for patients newly diagnosed with FA. These new FA screening assays would allow efficient testing of broad populations at risk...
  25. ncbi New developments in iron chelators
    Melody J Cunningham
    Harvard Medical School, Children s Hospital, Boston, MA 02115, USA
    Curr Opin Hematol 12:129-34. 2005
    ..Recently, several oral iron chelators and variations of deferoxamine to prolong the half-life have been developed. These and the methods of monitoring iron overload are the subjects of this review...
  26. ncbi RNA and protein evidence for haplo-insufficiency in Diamond-Blackfan anaemia patients with RPS19 mutations
    Hanna T Gazda
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 127:105-13. 2004
    ..Our data support the notion that, in addition to rare DBA patients with the deletion of one allele, the disease in certain other RPS19 mutant patients is because of RPS19 protein haplo-insufficiency...
  27. ncbi Academic freedom in clinical research
    David G Nathan
    Dana-Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 347:1368-71. 2002
  28. ncbi Stanley J. Korsmeyer
    David G Nathan
    Harvard Medical School, USA
    Proc Am Philos Soc 151:243-6. 2007
  29. ncbi Educational-debt relief for clinical investigators--a vote of confidence
    David G Nathan
    Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 346:372-4. 2002
  30. ncbi Sickle cell disease and stroke
    Luis A Verduzco
    Harvard Medical School, Boston, MA, USA
    Blood 114:5117-25. 2009
    ..Recent genome-wide association studies may provide methods for modulating fetal hemoglobin production enough to attenuate stroke risk and other complications of SCD...
  31. ncbi Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial
    Eric Nisbet-Brown
    Department of Paediatrics, Harvard Medical School, Boston, MA, USA
    Lancet 361:1597-602. 2003
    ..INTERPRETATION: ICL670 given once daily at 20 mg/kg seems to be an effective orally active iron chelator and is reasonably well tolerated. Long-term studies are now necessary to establish the practical contribution of this drug...
  32. ncbi Clinical research and the NIH--a report card
    David G Nathan
    Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, USA
    N Engl J Med 349:1860-5. 2003
  33. ncbi Obituary: Fred S. Rosen (1930-2005)
    Walter Gratzer
    Walter Gratzer is at King's College, The Randall Division, Guy's Campus, New Hunt's House, London SE1 1UL
    Nature 435:1044. 2005
  34. ncbi Search for improved therapy of sickle cell anemia
    David G Nathan
    J Pediatr Hematol Oncol 24:700-3. 2002
  35. ncbi Deferiprone and hepatic fibrosis
    Gary M Brittenham
    Blood 101:5089-90; author reply 5090-1. 2003